Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children
- 26 October 2009
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 45 (6) , 1052-1055
Abstract
EBV-associated post transplant lymphoproliferative disease (EBV-PTLD) is a life-threatening complication that may occur after hemopoietic SCT. We prospectively screened 80 children on a weekly basis using nested quantitative PCR to evaluate EBV genome copies. EBV viral load 5 PBMC was observed in 63% of transplants, whereas it was between 1000 and 9999 copies per 105 PBMC in 13%, and between 10 000 and 19 999 in 10%, with no significant increase in percentage of CD20+ lymphocytes. Viral load reached 20 000 copies per 105 PBMC in 14% of patients, and rituximab was administered to 75% of them. None of the patients except one developed a lymphoproliferative disease. Our study found that only 13% of unrelated donor HSCT recipients had a very high risk of EBV-PTLD defined as 20 000 geq per 105 PBMC associated with an increase in CD20+ lymphocyte. We suggest that rituximab could be administered in the presence of very high levels of EBV-DNA viral load or in the presence of mid levels of EBV-DNA viral load associated with an increase in the percentage of CD20+ lymphocytes. Through this approach, we significantly reduced the number of patients treated with rituximab, and consequently the acute and chronic adverse events related to this treatment.Keywords
This publication has 22 references indexed in Scilit:
- Unrelated hematopoietic stem cell transplantation for Cernunnos‐XLF deficiencyPediatric Transplantation, 2009
- Preemptive Management of Epstein-Barr Virus Reactivation After Hematopoietic Stem-Cell TransplantationTransplantation, 2009
- EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCTBone Marrow Transplantation, 2008
- Incidence of bacteremias and invasive mycoses in children undergoing allogeneic hematopoietic stem cell transplantation: a single center experienceBone Marrow Transplantation, 2007
- Management and Preparedness for Infusion and Hypersensitivity ReactionsThe Oncologist, 2007
- Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reactionScandinavian Journal of Infectious Diseases, 2007
- Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non‐Hodgkin's lymphomaHematological Oncology, 2006
- The impact of monitoring Epstein–Barr virus PCR in paediatric bone marrow transplant patients: Can it successfully predict outcome and guide intervention?Pediatric Blood & Cancer, 2005
- The real‐time polymerase chain reaction‐guided modulation of immunosuppression enables the pre‐emptive management of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantationBritish Journal of Haematology, 2004
- Pre-emptive therapy with rituximab for prevention of Epstein–Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantationBone Marrow Transplantation, 2003